News brief­ing: Gy­ro­scope and Ta­laris set IPO terms; FDA grants ex­pand­ed nod to Chiesi's sick­le cell drug

In a week where two biotech IPOs were al­ready ex­pect­ed, an­oth­er two prospec­tive en­trants have set their de­but terms ahead of their launch lat­er this week.

Gy­ro­scope Ther­a­peu­tics and Ta­laris Ther­a­peu­tics each set IPO terms Mon­day morn­ing. Gy­ro­scope, based out of the UK, is plan­ning to of­fer 6.8 mil­lion ADSs at a price range of $20 to $22, while Ta­laris ex­pects to of­fer 8.8 mil­lion shares be­tween $16 and $18 each.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER